Condition: Carcinoma, Non-Small Cell Lung · Sponsor: Genprex, Inc.
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.
This description comes directly from the study's public registry record.
Sr Director, Clinical Operations · 1-877-774-GNPX · kcombs@genprex.com
Chief Medical Officer · 1-877-774-GNPX · mberger@genprex.com
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree, Colorado, United States | Recruiting |
| Carle Cancer Institute | Urbana, Illinois, United States | Recruiting |
| Markey Cancer Center | Lexington, Kentucky, United States | Recruiting |
| Maryland Oncology Hematology | Rockville, Maryland, United States | Recruiting |
| The Valley Hospital - Luckow Pavilion | Paramus, New Jersey, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
| Millennium Oncology | Houston, Texas, United States | Terminated |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
| Virginia Oncology Associates | Norfolk, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04486833